Leland Allen, MD
Infectious Disease · Birmingham, ALNPI 1245258573
Payments from drug & device makers
Across 621 payments — averaging $13,650 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$7.5M
- Pfizer$951K
- Gilead$65K
- AbbVie$1K
- Merck$318
- Astellas Pharma US Inc$287
- plus $1K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 386 | $7,458,060 |
| Pfizer | 67 | $951,076 |
| Gilead | 14 | $64,851 |
| AbbVie(2 entities) | 65 | $1,000 |
| Merck | 19 | $318 |
| Astellas Pharma US Inc | 10 | $287 |
| Melinta Therapeutics, LLC | 11 | $240 |
| La Jolla Pharmaceutical Company | 10 | $204 |
| Novo Nordisk | 11 | $171 |
| Viiv Healthcare Company | 6 | $105 |
| AstraZeneca(2 entities) | 2 | $49 |
| Amgen | 3 | $47 |
| Amarin Pharma, Inc. | 3 | $37 |
| Insmed, Inc. | 1 | $33 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $33 |
| Mimedx Group, Inc. | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $21 |
| Fresenius USA Marketing, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Cumberland Pharmaceuticals, Inc. | 1 | $19 |
| GSK | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Pulmonx Corporation | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
How this compares
$8,476,711 in reported general payments places this provider in the 95th percentile of 104 infectious disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Birmingham
- Edgar OvertonBirmingham$2.8M
- Peter PappasBirmingham$2M
- John BaddleyBirmingham$1M
- Christina MuznyBirmingham$892K
- Sonya HeathBirmingham$801K
- Rena PatelBirmingham$512K
- Olivia van GerwenBirmingham$504K
- Paul GoepfertBirmingham$407K
- Todd McCartyBirmingham$339K
- Michael SaagBirmingham$339K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.